Blond psyllium (Plantago ovata) is supported by scientific evidence for its use in addressing certain aspects of metabolic syndrome, particularly dyslipidemia and impaired glycemic control. Multiple randomized controlled trials and meta-analyses demonstrate that psyllium supplementation can significantly reduce total cholesterol, LDL cholesterol, and fasting blood glucose levels in individuals with hyperlipidemia, type 2 diabetes, or metabolic syndrome. For instance, a 2018 meta-analysis in The American Journal of Clinical Nutrition found that psyllium supplementation lowered LDL cholesterol by an average of 0.28 mmol/L and reduced fasting blood glucose, with greater effects observed in people with higher baseline values.

The mechanism is thought to involve the viscous, gel-forming soluble fiber in psyllium, which delays gastric emptying, slows glucose absorption, and binds bile acids, thereby enhancing cholesterol excretion. While evidence for direct effects on all metabolic syndrome criteria (waist circumference, blood pressure, triglycerides) is less robust, improvements in lipid and glycemic parameters are clinically meaningful for metabolic syndrome management. Major guidelines (e.g., American Diabetes Association) acknowledge fiber supplements like psyllium as part of dietary therapy for metabolic syndrome-associated conditions.

Overall, while not a standalone treatment, blond psyllium is a scientifically validated adjunct in the management of metabolic syndrome, with a strong evidence base for its impact on cholesterol and blood sugar control.